Investigating how a specific protein affects nerve damage from chemotherapy
Official title: Damage-associated molecular patterns in chemotherapy toxicity
Funded at Ohio State University · NIH-11104906 · Data updated 2026-11-12
This study is looking at how a common cancer drug can cause nerve damage and pain, and it’s exploring a specific protein that might help reduce these side effects, so patients can feel better while getting their treatment.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $601,091 |
| NIH project number | 1R37CA299879-01 |
| Project ID | NIH-11104906 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients receiving paclitaxel who are experiencing or at risk of developing peripheral neuropathy.
✕Less likely to help
Patients who are not receiving paclitaxel or those with other types of neuropathy unrelated to chemotherapy may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind nerve damage caused by the chemotherapy drug paclitaxel, which is commonly used to treat cancers like breast and lung cancer. The study aims to identify a protein called S100A9 that may play a role in this nerve damage and neuroinflammation. By exploring how inhibiting S100A9 can potentially reduce the side effects of paclitaxel, the research seeks to improve treatment outcomes for patients experiencing painful nerve damage. Patients may be involved in trials that test new therapies targeting this protein to alleviate their symptoms.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce nerve damage and improve the quality of life for cancer patients undergoing chemotherapy.
How similar studies have gone: Previous research has shown promise in targeting similar molecular pathways to alleviate chemotherapy-induced side effects, suggesting potential for success in this approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Eisenmann, Eric Daniel — Ohio State University
- Study coordinator: Eisenmann, Eric Daniel
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.